glp 1 agonists approved for weight loss Are Serious Anesthesia Risks of Semaglutide and Other GLP-1 Under-Recognized? Case Reports of Retained Solid Gastric Contents in Patients Undergoing Anesthesia Study finds GLP-1 receptor agonists

For those navigating a breast cancer diagnosis, there is hope but also cautionespecially until larger studies can confirm which patients may benefit most and when these medications are safest to use

The milestones were specific development and approval triggers: $5/sh after Phase 3 start of the MET-097i + MET-233i combo trial

The idea that one can accurately identify delayed gastric emptying without performing imaging (such as bedside gastric ultrasound) is not rooted in reality

GLP-1, GIP & Inflammation: What These Medications Really Do and What They Dont Joshua Silva, MD Dec 5, 2025 7 min read Updated: Jan 27 Medically authored by Joshua Silva, MD | Evidence-Based Weight Loss at Potere Health MD Quick Answer GLP-1 and GLP-1/GIP medications (such as semaglutide and tirzepatide ) can lower metabolic inflammation by improving insulin resistance, reducing visceral fat, and lowering inflammatory biomarkers such as C-reactive protein (CRP) ., They can also improve cardiometabolic risk markers (e.g., blood pressure) and, for tirzepatide, can improve atherogenic lipoprotein measures including apoB and triglyceride-rich lipoproteins in clinical research settings., They do not treat autoimmune diseases or fibromyalgia directly

Output files were visualized in UCSF ChimeraX volume series and captured as movies(Goddard et al

Age-dependent human beta cell proliferation induced by glucagon-like peptide 1 and calcineurin signaling